News

CND Life Sciences Receives NIH Grant for Parkinson's Research

CND Life Sciences Receives NIH Grant for Parkinson's Research

CND Life Sciences Secures NIH Funding for Parkinson's Disease Study

The grant will support a comprehensive, three-year research project carried out in tandem with prominent medical institutions across the nation.

SCOTTSDALE, Ariz. — CND Life Sciences (CND), a pioneering company in the medical technology sector, has announced an exciting new collaboration backed by a $3 million grant from the National Institutes of Health (NIH) Small Business Innovation Research (SBIR) program. This funding will facilitate critical research to investigate whether the presence of phosphorylated alpha-synuclein (P-SYN) in patients who experience essential tremor (ET) indicates a higher likelihood of developing Parkinson's disease (PD).

The study, which is anticipated to yield significant insights, will leverage CND's innovative Syn-One Test as a predictive tool to determine which patients may be more susceptible to PD. The findings from this endeavor, referred to as the "Syn-T Study," are poised to have meaningful implications for the future treatment and management of ET patients.

The Significance of the Syn-T Study

"This is our fourth NIH-SBIR grant over the past five years, which serves as a strong validation of our scientific foundation and our capability to translate crucial neurodiagnostic advancements from theory into practice," stated Todd Levine, MD, chief medical officer and co-founder of CND. "The Syn-T Study is particularly vital within the neurodegeneration domain and for us at CND. With approximately seven million individuals in the U.S. living with essential tremor, the probability of developing Parkinson's disease is significantly amplified in these patients compared to the general populace. There is a clear demand from patients and healthcare providers for more information about the origins of tremor, and this research may provide the clarity they seek."

Exploring the Study's Objectives and Methodology

The aim of this expansive, three-year study is to ascertain if individuals diagnosed with ET exhibit P-SYN, a misfolded protein that potentially signals the early stages of PD. Essential tremor manifests as involuntary rhythmic shaking, typically observed in the hands, arms, legs, and head, adversely affecting the quality of life for many and contributing to disability. Statistically, this prevalent neurological condition affects more than five percent of those aged over 65, and it is linked with an increased probability of transitioning into Parkinson's disease.

Approximately 300 participants will take part in this important investigation, with recruitment expected to commence in the nearing months. The study will unfold across 15 sites throughout the U.S. under the expert supervision of three distinguished organizations: Baylor University Medical Center, University of Texas Southwestern Medical Center in Dallas, and Beth Israel Deaconess Medical Center in Boston, along with Drs. Joseph Jankovic, Elan Louis, and Ludy Shih leading the efforts.

Utilization of the Syn-One Test in Research

The research will implement the Syn-One Test, a diagnostic procedure involving a skin biopsy that yields vital pathological data to assist in evaluating individuals classified as 'at risk' for disorders associated with synucleinopathy, including Parkinson's disease. Utilizing an uncomplicated skin punch biopsy, researchers will measure the presence of P-SYN within the cutaneous nerve fibers of patients suffering from essential tremor.

Christopher Gibbons, MD, FAAN, chief scientific officer and co-founder of CND, emphasized the goals of this study: "Our objective is to establish that patients with essential tremor who receive positive results from the Syn-One Test possess a markedly higher probability of developing Parkinson's disease. Furthermore, we hope to illustrate that the accumulation rate of pathological alpha-synuclein is connected to the advancement of the disease. This knowledge will empower healthcare professionals with a deeper understanding of disease progression and better equip them with information to advise their patients regarding treatment options.”

Early Detection and Intervention as Primary Goals

Dr. Gibbons and his team also advocate for early identification as a critical step leading to timely interventions. As the medical community progresses toward creating groundbreaking therapies, it is essential for doctors to accomplish three pivotal actions: 1) detect the disease at its nascent stages, 2) initiate neuroprotective treatments promptly when they can be most effective, and 3) enhance focused monitoring and personalized care to ensure appropriate treatments are administered to each patient.

About CND Life Sciences

CND Life Sciences plays a crucial role in assisting patients facing the potential diagnosis of neurodegenerative conditions. With a CLIA-certified and CAP-accredited lab based in Scottsdale, Arizona, the company offers the Syn-One Test as a laboratory developed test (LDT) designed to help clinicians diagnose various synucleinopathies, including Parkinson’s disease. The Syn-One Test employs exclusive methods to detect phosphorylated alpha-synuclein in skin nerves while gauging other symptoms of peripheral nerve degeneration. Noteworthy findings from a prospective NIH-supported study about the Syn-One Test were recently published in the Journal of the American Medical Association (JAMA), demonstrating over 95% sensitivity in patients clinically diagnosed with specific synucleinopathies.

In addition to aiding in diagnostics, CND also collaborates with biopharmaceutical companies on clinical trials for new therapies and explores methods for early detection as well as synuclein quantification of neurodegenerative diseases.

Recognized as a Breakthrough Device by the U.S. Food and Drug Administration (FDA), the Syn-One Test is designed for the diagnosis of synucleinopathies in individuals aged 40 years and older who present clinical symptoms suggesting a synucleinopathy. The FDA’s Breakthrough Devices Program aims to accelerate the development and review process for medical devices that can provide more effective diagnoses and treatments for life-threatening conditions.

Frequently Asked Questions

What is the purpose of the NIH grant for CND Life Sciences?

The NIH grant will fund a study to assess whether the presence of the protein phosphorylated alpha-synuclein in essential tremor patients can predict the risk of developing Parkinson's disease.

How will the study be conducted?

The study will involve approximately 300 participants across 15 sites, utilizing the Syn-One Test through a straightforward skin biopsy procedure to monitor P-SYN levels.

Why is early detection important for Parkinson's disease?

Early detection can lead to timely interventions that may improve treatment effectiveness and patient outcomes, preserving quality of life.

What is the Syn-One Test?

The Syn-One Test is a diagnostic tool that analyzes skin biopsy samples to detect phosphorylated alpha-synuclein, aiding in the evaluation of synucleinopathies.

How does this research impact patients with essential tremor?

The research aims to provide clarity on the risks of developing Parkinson's disease, thus empowering patients and physicians with knowledge for better management of the condition.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

SanMar’s Lott Tops Promo Products Power 50 Again in 2026

Updated Category News Views 207

Branded hoodies and logo tumblers rarely make Wall Street’s pulse race, but the numbers behind them deserve a hard look. Jeremy Lott, president and CEO of SanMar, was named the most influential leader in the U.S. promotional-products business for the second consecutive year, taking No. 1 in the 2026 Counselor Power 50 ranking. Awards can be fluff. A repeat win beside...

Continue Reading
Concierto's Azure Push Puts Sovereignty on Display

Updated Category News Views 83

Sovereignty has become the corporate cloud world's favorite hard-edged word. Concierto is taking that word straight onto the Microsoft Ignite 2026 floor, and frankly, it is a sensible place to make the case. The company, part of Trianz, will appear as a Gamechanger Sponsor from November 17 through 20 at San Francisco's Moscone Center, showing its platform at Booth #5435....

Continue Reading
Navan’s Travel Survey Sells Friction as a Business Case

Updated Category News Views 167

A forgotten charger can turn a routine trip into a small mutiny. That is the useful little truth sitting underneath Navan’s new survey of 2,000 Americans who travel for leisure or business. The company is poking at the annoyances people carry from the bedroom packing pile to the jet bridge: forgotten items, rushed airport arrivals, pre-flight drinks, chatty strangers,...

Continue Reading
TRUSTA Targets AI Inference's GPU Memory Squeeze Hard

Updated Category News Views 87

GPU scarcity has turned ordinary server parts into strategic assets, and TRUSTA is leaning right into that uncomfortable fact at SuperComputing 2026. The enterprise-storage brand under ADATA is pitching an upgraded AI Scaler Toolkit built around a fairly sensible premise: companies running large-language-model inference should not have to buy another armful of expensive...

Continue Reading
AMP Tests Debt Market With €1.25 Billion Green Notes

Updated Category News Views 62

Refinancing season has arrived early at Ardagh Metal Packaging, and it is carrying a hefty €1.25 billion price tag. AMP has launched senior secured floating-rate green notes, with proceeds intended to retire two batches of secured debt due in 2028 and leave additional cash on the balance sheet for general corporate purposes, including capital expenditure. This is not...

Continue Reading
Linux Foundation Unveils the Global Fraud Alliance

Updated Category News Views 173

Who would have thought the tech wizards at the Linux Foundation would step up to tackle fraud on a global scale? That's what we've got with their latest play: the Open Financial Trust Alliance (OFTA). Launched at the Singapore FinTech Festival, they've got their sights on connecting the world's disconnected fraud fight. Think of it as a translator for the tangled mess of...

Continue Reading
Sola's 11-Step Push Makes Salon Ownership Less Blind

Updated Category News Views 296

A pristine studio does not pay rent by itself. That is the uncomfortable little truth sitting underneath Sola Salons’ new 11-step roadmap for beauty professionals considering salon-suite ownership. The company is telling stylists, estheticians, nail technicians, massage therapists, and other independent operators to treat the move from commission work to ownership like...

Continue Reading
LASIK Cost Math Deserves a Careful Second Look Today

Updated Category News Views 188

Thirty years of lens purchases can become a nasty tab Contact-lens spending has a funny way of staying invisible until somebody stacks the receipts into one ugly pile. A new cost-of-vision analysis from the surgeon advisory board of BestLASIKSurgeons.com says the average American contact-lens wearer may spend between $22,500 and $30,000 on corrective eyewear across 30...

Continue Reading
Docusign Pushes Contract Data Into ChatGPT Sales Tools

Updated Category News Views 187

Contracts are where sales momentum goes to get lost, buried under old PDFs, approval chains, and somebody’s half-finished CRM note. Docusign’s November 17, 2026 launch is a sensible attempt to drag that information into the place sellers may increasingly spend their working day: ChatGPT for Sales. The company’s new plugin lets a sales rep pull agreement intelligence...

Continue Reading
Paratus on the Move: Seagems JV Under the Microscope

Updated Category News Views 194

What's Cooking with Paratus Energy? Paratus Energy Services Ltd. (ticker: PLSV) just threw us a curveball, announcing a strategic review of its participation in the Seagems joint venture. Now, before you get too jazzed about ticker talk—hold your horses. No one's making any promises about transactions just yet. The decision's still hanging in the balance, even as they...

Continue Reading

Top 5 Most Recently Viewed Articles

Intuitive Machines Secures Major NASA Contract Worth $4.8 Billion

Updated Category News Views 85

Intuitive Machines Secures $4.8 Billion NASA Contract In the ever-changing landscape of space exploration, Intuitive Machines has recently landed a major contract from NASA worth up to $4.82 billion. This agreement aims to improve communication and navigation services for various near-space operations. Stock Prices Soar Following this announcement, Intuitive Machines saw...

Continue Reading
Cilantro Taco Grill Charts Ambitious Expansion Plans for 2025

Updated Category News Views 399

Cilantro Taco Grill Charts Ambitious Expansion Plans for 2025 The rapidly growing Cilantro Taco Grill has exciting plans to expand its footprint beyond the Chicagoland area in 2025, marking a pivotal moment in its journey. They are set to open their doors in new states, a development that signifies their success and commitment to delivering authentic Mexican flavors....

Continue Reading
Nightingale Ice Cream Sandwiches Launch Nationwide at Target

Updated Category News Views 242

Nightingale Ice Cream Sandwiches Launches in Target Stores Fans of ice cream sandwiches are in for a delightful treat as Nightingale Ice Cream Sandwiches is making its debut in select Target stores across the nation. This new venture brings signature chef-crafted flavors to shoppers, offering a taste of joy that has captured hearts and appetites. Your New Favorite Ice...

Continue Reading
Bybit Enhances User Experience with API for Flexible Savings

Updated Category News Views 180

Bybit Enhances User Experience with API for Flexible Savings Bybit, the world's second-largest cryptocurrency exchange by trading volume, has recently made a significant advancement by introducing API access for its On-Chain Earn and Flexible Savings products. This move aims to empower institutional users and developers to seamlessly connect with Bybit's infrastructure,...

Continue Reading
Empowering Indiana's Youth: The Impact of $30 Million Grant

Updated Category News Views 168

Transformative $30 Million Grant Boosts Youth Programs in Indiana An incredible investment from Lilly Endowment Inc. has led to remarkable growth and enhancement of programs across Indiana for Boys & Girls Club organizations. With a significant $30 million grant dedicated to expanding resources, mentorship, and safe spaces, clubs have been empowered to serve more young...

Continue Reading